戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 t and liver cirrhosis, and three people with drug-induced liver injury).
2 RUCAM in retrospectively-identified cases of drug induced liver injury.
3 ome liabilities such as moderate potency and drug induced liver injury.
4  delivery with a possible triggering role of drug induced liver injury.
5 y these reactions, focusing on idiosyncratic drug-induced liver injury.
6  offer better specificity in ruling out late drug-induced liver injury.
7 city (22.2 and 82.1%) for prediction of late drug-induced liver injury.
8 her sensitive nor specific for prediction of drug-induced liver injury.
9 iction of early and 22.2% and 63.7% for late drug-induced liver injury.
10  drug metabolism, drug-drug interaction, and drug-induced liver injury.
11  as sensitive and informative biomarkers for drug-induced liver injury.
12 lead the list of non-acetaminophen causes of drug-induced liver injury.
13  an important role in the protection against drug-induced liver injury.
14 e RUCAM is problematic for future studies of drug-induced liver injury.
15 fy the key publications of 2006 dealing with drug-induced liver injury.
16  disruption, and increased susceptibility to drug-induced liver injury.
17 tion of K8/18 is to protect hepatocytes from drug-induced liver injury.
18 iever but is also the most frequent cause of drug-induced liver injury.
19  a potential impact for pharmacokinetics and drug-induced liver injury.
20 3 inhibitors that could minimize the risk of drug-induced liver injury.
21 His liver histology was also consistent with drug-induced liver injury.
22 cholestasis, steatosis, viral hepatitis, and drug-induced liver injury.
23  drug reactions, with most attention paid to drug-induced liver injury.
24 portant therapeutic target for patients with drug-induced liver injury.
25 tabolic dysfunction predisposing patients to drug-induced liver injury.
26 ontributes to disease, such as silicosis and drug-induced liver injury.
27 lates what is believed to occur during human drug-induced liver injury.
28 engineering because of the high frequency of drug-induced liver injury.
29 s can cause severe, chronic liver disease or drug-induced liver injury.
30 based instruments for assessing causality in drug-induced liver injury.
31 amic behaviour in the biological response to drug-induced liver injury.
32 ies have evaluated the incidence of ALF from drug-induced liver injury.
33 y revealed signs of immune-mediated toxic or drug-induced liver injury.
34 cells in human leukocyte antigen-associated, drug-induced liver injury.
35  biopsy samples from patients suffering from drug-induced liver injury.
36 elevance for understanding the regulation of drug-induced liver injury.
37            Among 318 patients with suspected drug-induced liver injury, 50 (16%) tested positive for
38 8 patients included, and 21 (7.3%) developed drug-induced liver injury (57.1% "early" at 2 wk and 42.
39 edominant pathological features were that of drug induced liver injury, although an abnormal amount o
40 ug-related serious adverse events (potential drug-induced liver injury and depression or lipodystroph
41 -induced liver injury group compared with no drug-induced liver injury and late drug-induced liver in
42 entification of a subgroup who develop early drug-induced liver injury and may offer better specifici
43 ophen (APAP) overdose is a frequent cause of drug-induced liver injury and the most frequent cause of
44 udy: hospitalization, colitis, and potential drug-induced liver injury) and one of four patients had
45 restlessness, tendon disorder, and potential drug-induced liver injury) and one of four patients had
46                            Anti-tuberculosis drug induced liver injury (Anti-TB DILI) is the most com
47 sts that many cases of serious idiosyncratic drug-induced liver injury are mediated by the adaptive i
48                      Host factors leading to drug-induced liver injury are not yet well understood.
49 alized adult patients with anti-tuberculosis drug induced liver injury (AT-DILI).
50 alized adult patients with anti-tuberculosis drug-induced liver injury (AT-DILI).
51            The biosensor is able to detect a drug-induced liver injury by monitoring the oxidative st
52                                A total of 40 drug-induced liver injury cases were enrolled including
53                                              Drug-induced liver injury caused by acetaminophen (acety
54  of metal transporters in cellular models of drug-induced liver injury caused by acetaminophen overdo
55                       New onset or worsening drug-induced liver injury challenges coinfected patients
56 prospective study of patients with suspected drug-induced liver injury; clinical information and biol
57 29%), indeterminate ALF (23%), idiosyncratic drug-induced liver injury DILI (22%), acute hepatitis B
58                                              Drug induced liver injury (DILI) is a necro-inflammatory
59                                              Drug induced liver injury (DILI) is an important cause o
60                                Idiosyncratic drug induced liver injury (DILI) remains poorly understo
61                                              Drug-induced liver injury (DILI) accounts for 20-40% of
62                                 Diagnosis of drug-induced liver injury (DILI) and its distinction fro
63                  Liver biology and function, drug-induced liver injury (DILI) and liver diseases are
64 blood biomarkers are suboptimal in detecting drug-induced liver injury (DILI) and predicting its outc
65       Little is known about the incidence of drug-induced liver injury (DILI) and risk factors for ad
66                           The association of drug-induced liver injury (DILI) and Stevens-Johnson syn
67 ic health concern in the United States, with drug-induced liver injury (DILI) being the single most c
68                                              Drug-induced liver injury (DILI) causes one in three mar
69                                              Drug-induced liver injury (DILI) developed in 26 (7.9%)
70                                              Drug-induced liver injury (DILI) due to amoxicillin-clav
71 hilia has been associated with incidences of drug-induced liver injury (DILI) for more than 50 years,
72                                Patients with drug-induced liver injury (DILI) frequently have comorbi
73                               Distinguishing drug-induced liver injury (DILI) from idiopathic autoimm
74           We investigated the role of JNK in drug-induced liver injury (DILI) in liver tissue from pa
75   Under standard therapies, the incidence of drug-induced liver injury (DILI) in patients with tuberc
76       Little is known about the incidence of drug-induced liver injury (DILI) in the general populati
77                                              Drug-induced liver injury (DILI) is a challenging proble
78                                              Drug-induced liver injury (DILI) is a common disorder th
79                                              Drug-induced liver injury (DILI) is a leading cause of d
80 rition in drug discovery and development and drug-induced liver injury (DILI) is a leading cause of p
81                                              Drug-induced liver injury (DILI) is a leading cause of t
82                                              Drug-induced liver injury (DILI) is a main cause of drug
83                                              Drug-induced liver injury (DILI) is a major challenge in
84                                              Drug-induced liver injury (DILI) is a major health issue
85                                              Drug-induced liver injury (DILI) is a major public healt
86                                              Drug-induced liver injury (DILI) is a major safety conce
87                                              Drug-induced liver injury (DILI) is a patient-specific,
88                                Idiosyncratic drug-induced liver injury (DILI) is a rare disease that
89                                Idiosyncratic drug-induced liver injury (DILI) is a rare disorder that
90                                Idiosyncratic drug-induced liver injury (DILI) is a rare, often diffic
91                                Idiosyncratic drug-induced liver injury (DILI) is among the most commo
92                                              Drug-induced liver injury (DILI) is an adverse reaction
93                                Idiosyncratic drug-induced liver injury (DILI) is an important but rel
94                                              Drug-induced liver injury (DILI) is an important cause o
95                                              Drug-induced liver injury (DILI) is an important cause o
96                                              Drug-induced liver injury (DILI) is an important cause o
97                                              Drug-induced liver injury (DILI) is considered to be a d
98              The diagnosis and management of drug-induced liver injury (DILI) is hindered by the limi
99                                              Drug-induced liver injury (DILI) is largely a diagnosis
100                                              Drug-induced liver injury (DILI) is of major interest to
101                                              Drug-induced liver injury (DILI) is one of the most sign
102  cytokeratin-18 (K18), accurate detection of drug-induced liver injury (DILI) is possible.
103                                              Drug-induced liver injury (DILI) is the leading cause of
104                             The detection of drug-induced liver injury (DILI) is therefore of importa
105                                Idiosyncratic drug-induced liver injury (DILI) is traditionally though
106                                              Drug-induced liver injury (DILI) limits the development
107                                              Drug-induced liver injury (DILI) may present any morphol
108 nd important data published on idiosyncratic drug-induced liver injury (DILI) over the past 2 years i
109                                              Drug-induced liver injury (DILI) presents a significant
110                                              Drug-induced liver injury (DILI) remains a leading cause
111                           PURPOSE OF REVIEW: Drug-induced liver injury (DILI) remains an important di
112                                              Drug-Induced Liver Injury (DILI) remains one of the most
113 ethnic cohort of patients with idiosyncratic drug-induced liver injury (DILI) to identify variants as
114                             Immune-mediated, drug-induced liver injury (DILI) triggered by drug hapte
115                   We assessed both cases for drug-induced liver injury (DILI) using the updated score
116   Hy's Law, which states that hepatocellular drug-induced liver injury (DILI) with jaundice indicates
117 (SMX) is an important cause of idiosyncratic drug-induced liver injury (DILI), but its genetic risk f
118 lay an important role in the pathogenesis of drug-induced liver injury (DILI), but supporting data ar
119 patients, but statins rarely lead to serious drug-induced liver injury (DILI), chronic liver disease,
120             Acute liver failure (ALF) due to drug-induced liver injury (DILI), though uncommon, is a
121 anti-inflammatory drug diclofenac may induce drug-induced liver injury (DILI).
122 a hepatocyte-specific microRNA biomarker for drug-induced liver injury (DILI).
123 roxen (NAP) is associated with idiosyncratic drug-induced liver injury (DILI).
124  opening new avenues for targeted therapy in drug-induced liver injury (DILI).
125 i-inflammatory drugs (NSAIDS) that result in drug-induced liver injury (DILI).
126 ology, which serves as surrogate readout for Drug-Induced Liver Injury (DILI).
127 or exposure to drug safety concerns, such as drug-induced liver injury (DILI).
128    Toxic liver diseases are mainly caused by drug-induced liver injury (DILI).
129               Antidepressant drugs can cause drug-induced liver injury (DILI).
130 RTs and anti-TBs are at an increased risk of drug-induced liver injury (DILI).
131 e associated with positive rechallenge after drug-induced liver injury (DILI): antimicrobials; and ce
132 on tasks with distinct modalities: filtering drug-induced-liver-injury (DILI) literature with free-te
133  adults with nevirapine hypersensitivity (15 drug-induced liver injury [DILI], 33 SJS/TEN, 20 hyperse
134                   In a high HIV burden area, drug-induced liver injury due to antiretroviral therapy
135 er injury and could be useful for monitoring drug-induced liver injury during drug discovery.
136                         Among 1,188 cases of drug-induced liver injury enrolled between 2004 and 2012
137                                 All cases of drug-induced liver injury enrolled into a prospective da
138 chaemia, viral and autoimmune hepatitis, and drug-induced liver injury from prescription drugs, and h
139                                              Drug-induced liver injury from statins is rare and chara
140  individuals with HIV infection in the early drug-induced liver injury group compared with no drug-in
141 d with no drug-induced liver injury and late drug-induced liver injury groups (33% vs. 7.1% vs. 0%; P
142                             A role of FXR in drug-induced liver injury has also been hypothesized yet
143                                 Two types of drug induced liver injury have been recognized: intrinsi
144               The mechanism of idiosyncratic drug-induced liver injury (IDILI) remains poorly underst
145 adverse drug reactions such as idiosyncratic drug-induced liver injury (iDILI).
146                                   Predicting drug-induced liver injury in a preclinical setting remai
147 ty to discuss challenges in the diagnosis of drug-induced liver injury in an era of increasing awaren
148 -induced liver injury in mice is a model for drug-induced liver injury in humans.
149 th it several reminders of the importance of drug-induced liver injury in the clinical trial as well
150 equency of HEV infection among patients with drug-induced liver injury in the United States.
151 taminophen is the most common cause of acute drug-induced liver injury in the United States.
152                                              Drug-induced liver injury is a frequent side effect of m
153                                              Drug-induced liver injury is a major safety issue.
154                                              Drug-induced liver injury is an important clinical entit
155                   Drug rechallenge following drug-induced liver injury is associated with up to 13% m
156 of treated patients, but clinically apparent drug-induced liver injury is rare.
157          Bile duct loss during the course of drug-induced liver injury is uncommon, but can be an ind
158  important element in assessing causality in drug-induced liver injury is whether the implicated agen
159  important feature of the normal response to drug-induced liver injury may be the increased expressio
160     However, the complexity of idiosyncratic drug-induced liver injury means that no current single-c
161 ize pathological levels of nitric oxide in a drug-induced liver injury model via deep tissue SWIR pho
162 ally eliminated reactive oxygen species in a drug-induced liver injury model.
163 rospective study of subjects enrolled in the Drug Induced Liver Injury Network (DILIN) from 2004 to 2
164 d 2012 in a prospective registry by the U.S. Drug Induced Liver Injury Network, 22 were attributed to
165 ses of patients with DILI (the United States Drug Induced Liver Injury Network, DILIGEN, and the Span
166 ective, observational study conducted by the Drug Induced Liver Injury Network.
167 ght to improve the RUCAM using data from the Drug-Induced Liver Injury Network (DILIN) and the Spanis
168                                          The Drug-Induced Liver Injury Network (DILIN) is a prospecti
169                                       The US Drug-Induced Liver Injury Network (DILIN) prospective st
170                                          The Drug-Induced Liver Injury Network (DILIN) studies hepato
171 ation that will soon be made possible by The Drug-Induced Liver Injury Network (DILIN).
172                                          The Drug-Induced Liver Injury Network is conducting a prospe
173                                          The Drug-Induced Liver Injury Network is enrolling well-defi
174  mortality) for 306 patients enrolled in the Drug-Induced Liver Injury Network prospective study at I
175               We analyzed patients in the US Drug-Induced Liver Injury Network prospective study havi
176    Among 1,414 patients enrolled in the U.S. Drug-Induced Liver Injury Network who underwent formal c
177 terile inflammation (SI) is a key process in drug-induced liver injury, nonalcoholic steatohepatitis,
178                                              Drug-induced liver injury occurred in 8.0% of the partic
179  the standard-dose group, but no deaths from drug-induced liver injury occurred.
180 ment group (encephalopathy, hepatic failure, drug-induced liver injury, oesophageal varices haemorrha
181 levels of alanine aminotransferase (ALT) for drug-induced liver injury often assume that the biomarke
182  few years, with most cases now arising from drug-induced liver injury, often from paracetamol.
183                       There were no cases of drug-induced liver injury or clinically relevant hepatic
184                     There were no reports of drug-induced liver injury or deaths across the groups.
185 rt represents the second documented cases of drug-induced liver injury related to varenicline therapy
186                             The diagnosis of drug-induced liver injury relies on exclusion of other c
187                                              Drug-induced liver injury remains an important concern f
188                    Although the frequency of drug-induced liver injury remains low, new data from the
189 nical features, evaluation and mechanisms of drug-induced liver injury reported during 2007.
190  in the world and accounts for most cases of drug induced liver injury resulting in acute liver failu
191 pon admission before the start of treatment, drug-induced liver injury should be taken into considera
192 ng clinical evaluation and stopping rules of drug-induced liver injury signals, including Hy's Law ca
193 idrug and autoAbs has been observed in other drug-induced liver injury that is presumed to be immune
194 Conclusion: Telithromycin is a rare cause of drug-induced liver injury that may have a distinctive cl
195                                              Drug-induced liver injury, viral hepatitis, and metaboli
196 al for chronic injury to develop after acute drug-induced liver injury was analyzed in a large Swedis
197                                              Drug-induced liver injury was evaluated on the basis of
198 vents reporting and experience in evaluating drug-induced liver injury was formed, including members
199 No evidence of cholestatic hepatotoxicity or drug-induced liver injury was noted.
200                                              Drug-induced liver injury was of difficult interpretatio
201                                              Drug-induced liver injury was the predominant finding (4
202                       While no new causes of drug-induced liver injury were reported for 2004, severa
203  acute liver failure in western countries is drug-induced liver injury, while it has rarely been repo
204  clinical features, and outcomes of cases of drug-induced liver injury with histologically proven bil

 
Page Top